Compare Amcor PLC (AMCR) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amcor PLC vs Smith & Nephew plc — how do they compare? Amcor PLC trades at $47.17 (market cap $21.92B), while Smith & Nephew plc trades at $29.82 (market cap $12.54B). The key difference: Amcor PLC is the larger of the two by market cap, and Amcor PLC pays the higher dividend (5.49%). Which is the better fit depends on your goals.
| AMCR | SNN | |
|---|---|---|
Market Cap | $21.92B | $12.54B |
Sector | Basic Materials | Health |
52-Week High | $50.58 | $38.70 |
52-Week Low | $36.69 | $28.73 |
Enterprise Value | $37.03B | $15.57B |
Dividend Yield | 5.49% | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMCR trades at $46.85, down 0.55% today, with a bullish technical outlook supported by moving averages and strong earnings beats in the last four quarters. The company reported Q2 2026 EPS of $1.23, exceeding estimates, and maintains a 64% analyst buy rating with a $47.00 consensus target. Recent news highlights expansion in China and strong Q4 results, though net income margin declined to 3.06% in 2025.
The stock presents a balanced opportunity with solid earnings performance and analyst support, but risks include elevated P/E of 38.07, margin pressure, and high debt levels. Upside is capped near-term by technical resistance at $48, while support lies at $46.
Smith & Nephew (SNN) trades at $29.76, down 1.06% with bearish technical signals. The company shows improving fundamentals with revenue growth from $5.8B to $6.2B and net income margin expanding to 10.08% in 2025. Recent Q2 2026 earnings beat expectations but the company lowered full-year revenue guidance from 6% to 4% growth due to U.S. Orthopaedics weakness.
While valuation multiples appear reasonable (P/E 20.41, EV/EBITDA 9.9), the stock faces headwinds from mixed earnings performance and cautious analyst sentiment. The primary investment case hinges on execution in robotics and wound care segments offsetting orthopedic challenges, with downside risk from continued U.S. market softness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amcor PLC
Amcor is a global plastics packaging behemoth, with global sales of USD 14.5 billion in fiscal 2022 following the acquisition of Bemis in 2019. Amcor's operations span over 40 countries globally and include significant emerging-market exposure equating to circa 20% of sales. Amcor's capabilities span flexible and rigid plastic packaging, which sell into defensive food, beverage, healthcare, household, and personal-care end markets.
Read more on AMCR →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
